Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardiff LexingtonCDIX +0.79%27 EBITDA Margin % is -52.61% as of Mar. 2026. GuruFocus rates CDIX with a GF Score™ of 27/100 and a GF Value™ of $0.08 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 664 Healthcare Providers & Services companies, Cardiff Lexington ranks worse than 80.12% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cardiff Lexington's EBITDA for the
three
months ended in Mar. 2026 was $-1.17 Mil. Cardiff Lexington's Revenue for the
three
months ended in Mar. 2026 was $2.22 Mil. Therefore, Cardiff Lexington's EBITDA margin for the quarter that ended in Mar. 2026 was -52.61%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Cardiff Lexington EBITDA Margin % Related Terms
Cardiff Lexington EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Cardiff Lexington's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CDIX vs AMS, SYRA, BMGL: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Cardiff Lexington's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiff Lexington EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cardiff Lexington's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Cardiff Lexington's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiff Lexington (CDIX) has a EBITDA Margin % of -52.61% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cardiff Lexington and its competitors. According to the industry distribution chart, Cardiff Lexington ranks #532 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 80.1%.
Is Cardiff Lexington's EBITDA Margin % too high?
Cardiff Lexington's current EBITDA Margin % is -52.61%. Based on the distribution chart, Cardiff Lexington ranks #532 out of 664 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Cardiff Lexington has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cardiff Lexington's EBITDA Margin % compare to AMS and SYRA?
According to the Healthcare Providers & Services industry distribution chart, Cardiff Lexington ranks #532 out of 664 companies for EBITDA Margin %. This places Cardiff Lexington in the lower half of its industry. The industry median EBITDA Margin % is 10.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cardiff Lexington and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiff Lexington's current EBITDA Margin % is -52.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Lexington stock overvalued right now?
Based on GuruFocus' analysis, Cardiff Lexington (CDIX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.08, compared to a current price of $0.51 — trading 537.5% above its estimated fair value. The current EBITDA Margin % is -52.61%. Cardiff Lexington's overall GF Score™ is 27/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cardiff Lexington (CDIX), the current EBITDA Margin % is -52.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cardiff Lexington (CDIX) Overvalued in 2026?
Based on GuruFocus' analysis, Cardiff Lexington stock appears to be overvalued.
The current stock price of $0.51 is trading 537.5% above its estimated GF Value™ of $0.08.
GuruFocus considers Cardiff Lexington to be Significantly Overvalued.
Key valuation signals for CDIX:
EBITDA Margin %: -52.61%
GF Value™: $0.08 vs. price of $0.51 (537.5% above fair value)
No single metric tells the full story. See the CDIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cardiff Lexington Corp is an acquisition holding company, conducting its operations through its operating subsidiaries. The company has two reportable operating segments; Healthcare (Nova), and Real Estate (Edge View). The Healthcare segment generates all of the company's revenue and provides a full range of diagnostic and surgical services for injuries and disorders of the skeletal system and associated bones, joints, tendons, muscles, ligaments, and nerves. The Real estate segment consists of Edge View, a real estate company that owns various acres zoned medium-density residential.
27GF Score
Get the complete analysis for CDIX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CDIX has been successfully added to your 
